BACKGROUND: Chronic, inappropriate (relative to dietary Na+) elevations in circulating aldosterone, such as occur in congestive heart failure, are accompanied by a proinflammatory vascular phenotype involving the coronary and systemic vasculature. An immunostimulatory state with activated peripheral blood mononuclear cells (PBMCs) precedes this phenotype and is induced by a fall in cytosolic free [Mg2+]i and subsequent Ca2+ loading of these cells and transduced by oxidative/nitrosative stress. METHODS AND RESULTS: We sought to further validate this hypothesis in rats with aldosterone/1%NaCl treatment (ALDOST) by using several interventions as cotreatment: a Mg2+-supplemented diet; amlodipine, a CCB; and N-acetylcysteine, an antioxidant. Blood samples were obtained at weeks 1 to 4 of ALDOST to monitor [Mg2+]i, [Ca2+]I, and H2O2 production in PBMCs. Coronal ventricular sections were examined for invading inflammatory cells and 3-nitrotyrosine labeling, a marker of oxidative/nitrosative stress. In response to ALDOST and compared with untreated controls, we found an early and persistent reduction in [Mg2+]i with a subsequent rise in [Ca2+]i and H2O2 production, each of which was either attenuated or abrogated by the Mg2+-supplemented diet and by N-acetylcysteine, whereas amlodipine prevented Ca2+ loading and an altered redox state. Cotreatment with these interventions either markedly attenuated or prevented the appearance of the proinflammatory coronary vascular phenotype and the presence of 3-nitrotyrosine in invading inflammatory cells. CONCLUSIONS: We suggest that the immunostimulatory state that appears during aldosteronism and leads to a proinflammatory coronary vascular phenotype is induced by a fall in [Mg2+]i with Ca2+ loading of PBMCs and is transduced by H2O2 production in these cells.
BACKGROUND: Chronic, inappropriate (relative to dietary Na+) elevations in circulating aldosterone, such as occur in congestive heart failure, are accompanied by a proinflammatory vascular phenotype involving the coronary and systemic vasculature. An immunostimulatory state with activated peripheral blood mononuclear cells (PBMCs) precedes this phenotype and is induced by a fall in cytosolic free [Mg2+]i and subsequent Ca2+ loading of these cells and transduced by oxidative/nitrosative stress. METHODS AND RESULTS: We sought to further validate this hypothesis in rats with aldosterone/1%NaCl treatment (ALDOST) by using several interventions as cotreatment: a Mg2+-supplemented diet; amlodipine, a CCB; and N-acetylcysteine, an antioxidant. Blood samples were obtained at weeks 1 to 4 of ALDOST to monitor [Mg2+]i, [Ca2+]I, and H2O2 production in PBMCs. Coronal ventricular sections were examined for invading inflammatory cells and 3-nitrotyrosine labeling, a marker of oxidative/nitrosative stress. In response to ALDOST and compared with untreated controls, we found an early and persistent reduction in [Mg2+]i with a subsequent rise in [Ca2+]i and H2O2 production, each of which was either attenuated or abrogated by the Mg2+-supplemented diet and by N-acetylcysteine, whereas amlodipine prevented Ca2+ loading and an altered redox state. Cotreatment with these interventions either markedly attenuated or prevented the appearance of the proinflammatory coronary vascular phenotype and the presence of 3-nitrotyrosine in invading inflammatory cells. CONCLUSIONS: We suggest that the immunostimulatory state that appears during aldosteronism and leads to a proinflammatory coronary vascular phenotype is induced by a fall in [Mg2+]i with Ca2+ loading of PBMCs and is transduced by H2O2 production in these cells.
Authors: Atta U Shahbaz; Tieqiang Zhao; Wenyuan Zhao; Patti L Johnson; Robert A Ahokas; Syamal K Bhattacharya; Yao Sun; Ivan C Gerling; Karl T Weber Journal: Am J Physiol Heart Circ Physiol Date: 2010-11-12 Impact factor: 4.733
Authors: Malay S Gandhi; Prajwal A Deshmukh; German Kamalov; Tieqiang Zhao; Wenyuan Zhao; Jonathan T Whaley; Jill R Tichy; Syamal K Bhattacharya; Robert A Ahokas; Yao Sun; Ivan C Gerling; Karl T Weber Journal: J Cardiovasc Pharmacol Date: 2008-09 Impact factor: 3.105
Authors: Arne Yndestad; Jan Kristian Damås; Erik Oie; Thor Ueland; Lars Gullestad; Pål Aukrust Journal: Heart Fail Rev Date: 2006-03 Impact factor: 4.214
Authors: A Grotevendt; H Wallaschofski; M Reincke; C Adolf; M Quinkler; M Nauck; W Hoffmann; R Rettig; A Hannemann Journal: Endocrine Date: 2017-06-22 Impact factor: 3.633
Authors: Bradley A Maron; Ying-Yi Zhang; Diane E Handy; Annie Beuve; Shiow-Shih Tang; Joseph Loscalzo; Jane A Leopold Journal: J Biol Chem Date: 2009-01-13 Impact factor: 5.157
Authors: C A Carvajal; A A Herrada; C R Castillo; F J Contreras; C B Stehr; L M Mosso; A M Kalergis; C E Fardella Journal: J Endocrinol Invest Date: 2009-10 Impact factor: 4.256
Authors: German Kamalov; Robert A Ahokas; Wenyuan Zhao; Tieqiang Zhao; Atta U Shahbaz; Patti L Johnson; Syamal K Bhattacharya; Yao Sun; Ivan C Gerling; Karl T Weber Journal: J Cardiovasc Pharmacol Date: 2010-03 Impact factor: 3.105